Market Potential of Carbon Dioxide Nasal Spray

Status Completed

Clinical Trial Summary

Carbon dioxide (CO2) is a naturally occurring gas that readily diffuses across body tissues and membranes. Data from earlier clinical studies conducted in 975 subjects with allergic rhinitis have shown that nasally administered CO2 may provide relief of the associated symptoms. Symptom relief has been shown to occur as soon as 10 minutes after administration, and may persist for four to six hours.

This study aims to assess the consumer appeal of a prototype CO2 delivery device, as well as evaluate its perceived effectiveness for nasal congestion. Properly consented subjects who qualify and choose to participate in the clinical study will be administered nasal CO2 under medical supervision, wait a period of 1 hour in clinic, and then be dispensed a device for self-treatment at home. Subjects will return to the clinic on day 7 for final evaluation and completion of assessment questionnaires.

Clinical Trial Description

This study will be conducted in two parts. In the first part of the study, recruited subjects with nasal congestion will view a description of a new treatment option (concept). Interested subjects will be offered the opportunity to enter the clinical trial. Subjects who consent and are found otherwise eligible will then receive one dose of CO2 in the study clinic under medical supervision. Afterward, subjects who wish to continue will be allowed to take the administration device home for an additional six days of use (study part 2).

During the at-home use portion of the study, subjects will use a diary to record the number of times the product was used and their nasal congestion symptoms before and after use.

At the end of the study period, subjects will return to the study center for global assessment of their impressions of treatment and to answer questions designed to estimate market acceptability. Subjects may be asked to participate voluntarily in a market research focus group following their participation in this study. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Nasal Congestion

Clinical Trial Details

NCT number	NCT02113449
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 2
Start date	November 2013
Completion date	February 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00665977` - Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure	Phase 3
Completed	`NCT05843071` - PMCF Study to Evaluate Performance and Safety of "NASAL SPRAYS " Used to Relieve Nasal Congestion and Dryness	N/A
Completed	`NCT00957996` - Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza	Phase 3
Completed	`NCT00829634` - Steady State Kinetics of l-Methamphetamine and Validation of Sensitivity of Dose Estimation	N/A
Completed	`NCT00662337` - Bioequivalence Between Two Oral Formulations of Diphenhydramine Hydrochloride	Phase 1
Completed	`NCT05247333` - Implementation of a Minor Ailment Service in Community Pharmacy Practice	N/A
Recruiting	`NCT05244148` - Two Seawater-based Formulations for Relief of Nasal Congestion in Paediatric Subjects	N/A
Completed	`NCT05159271` - Efficacy and Safety of Azeol Nasal Spray Versus Placebo in the Treatment of Early Symptoms of Common Cold in Adults	N/A
Terminated	`NCT00958776` - A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza	Phase 3
Completed	`NCT00648973` - To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses	Phase 4
Completed	`NCT03399721` - Investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the Treatment of Non Allergic Rhinitis	N/A
Completed	`NCT01354418` - Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED)	Phase 1
Completed	`NCT04797936` - BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19	Phase 4
Completed	`NCT03906968` - The Safety and Efficacy of a SinuSonic Intervention	N/A
Completed	`NCT02100605` - Study on Hypertonic Saline Nasal Spray	N/A
Recruiting	`NCT06323304` - Efficacy and Safety of Auricular Acupressure in Treating Allergic Rhinitis	N/A
Withdrawn	`NCT04790487` - Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis	Phase 2/Phase 3
Completed	`NCT01448057` - Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu	Phase 3
Completed	`NCT01129765` - Home Usability of a Nasal Lavage System in Children	N/A
Completed	`NCT04910139` - A User Study of the Soniflow System for Nasal Congestion Relief	N/A